Showing results (81-90 of 155) with videos related to

Sort By:
Pageof 16
ESMO Open|May 13, 2020
ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracyJose Luis Perez-Gracia, Ahmad Awada, Emiliano Calvo, et al.
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Investigational New Drugs|March 20, 2020
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRJames M Cleary, Emiliano Calvo, Victor Moreno, et al.
The Oncologist|January 20, 2025
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancerEmiliano Calvo, Bernard Doger, Joan Carles, et al.
Clinical Epigenetics|July 9, 2026
Tumor-type specific methylation patterns of MTAP in human samples and cell linesLuis Álvarez-Carrión, Dalma Müller, Manuel Pedregal, et al.
ACS Omega|December 1, 2025
Understanding the Chemical Characteristics of Payloads and the Expression of Tumor-Associated Antigens of ADCs in Clinical DevelopmentCristina Nieto-Jiménez, Lucía Paniagua-Herranz, Carlo Bosi, et al.
Investigational New Drugs|March 11, 2021
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I studyMaría Eugenia Olmedo, Martin Forster, Victor Moreno, et al.
Frontiers in Oncology|March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapiesChristin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast CancerSara M Tolaney, Young-Hyuck Im, Emiliano Calvo, et al.
British Journal of Cancer|May 26, 2023
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumorsAnthony B El-Khoueiry, James Clarke, Tobias Neff, et al.
Pageof 16